As bird flu continues to circulate in animals and spill over into humans, researchers are racing to stop it before it adapts ...

Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

The effectiveness of last season's COVID vaccines among immunocompetent adults reached 40% against hospitalization and 79% ...

Moderna, Inc. stock is up ~60% YTD on cancer vaccine trial data, 2026 readouts, and 2025 financials. Click for this updated ...

Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and ...

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

The Convergence of mRNA Technology, Universal Vaccine Research, and Post-Pandemic Health Policies Creates a Trillion-Dollar ...

Officials have confirmed bird flu in a backyard flock in Ottawa County, marking Michigan’s first case of the year.

Moderna chief executive officer Stephane Bancel said the company does not plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from health officials in the ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

At the World Economic Forum, CEO Stéphane Bancel expressed concern about the US vaccine market but remained committed to cancer and rare disease mRNA programs.

MRNA shares rise after upbeat 2025 sales, stronger cash outlook and detailed 2026 guidance, alongside multiple pipeline milestones.